Richard T. Kenney - Jun 30, 2025 Form 4 Insider Report for Sonnet BioTherapeutics Holdings, Inc. (SONN)

Role: Chief Medical Officer
Signature: /s/ Richard T. Kenney
Stock symbol: SONN
Transactions as of: Jun 30, 2025
Transactions value $: $0
Form type: 4
Date filed: 8/21/2025, 04:48 PM
Previous filing: Dec 5, 2024
Next filing: Jul 15, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kenney Richard T	Chief Medical Officer	100 OVERLOOK CENTER, SUITE 102, PRINCETON,	/s/ Richard T. Kenney	2025-08-21	0001606653

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SONN	Warrant	Award		+86.5K			86.5K	Jun 30, 2025	Common Stock	86.5K	$1.16	Direct	F1
transaction	SONN	Warrant	Award		+320K			320K	Jul 14, 2025	Common Stock	320K	$1.25	Direct	F2
transaction	SONN	Series 5 Preferred Stock	Award		+200			200	Jul 14, 2025	Common Stock	160K	$1.25	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 30, 2025, the Reporting Person was issued warrants to purchase up to 86,505 shares of common stock, par value $0.0001 ("Common Stock") as partial consideration for a convertible note (the "Convertible Note") issued by the Company in favor of the Reporting Person in the principal amount of $200,000. The Convertible Note and warrants cannot be converted or exercised, respectively, to the extent that, after giving effect to such conversion or exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock.
F2	On July 14, 2025, the Reporting Person was issued warrants to purchase up to 320,000 shares of Common Stock upon the conversion in full of the Convertible Note. The warrants cannot be exercised to the extent that, after giving effect to such exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock.
F3	On July 14, the Reporting Person was issued 200 shares of Series 5 Preferred Stock, initially convertible at a conversion price of $1.25 per share upon the conversion in full of the Convertible Note. The Series 5 Preferred Stock cannot be converted to the extent that, after giving effect to such conversion, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock. The Series 5 Preferred Stock is perpetual and therefore has no expiration date.